WHO Executive Board Adopts Draft Resolution On TB, Stresses Importance Of Resistant TB In Overall Fight Against AMR 05/02/2018 Health Policy Watch Mirza Alas of the intergovernmental South Centre has published an analysis of the World Health Organization Executive Board approval of a draft resolution on actions toward ending tuberculosis and how it relates to antimicrobial resistance (AMR). The opening paragraphs and a link to the original are provided below. Continue reading -> “We Must Engage With Industry” – WHO Director Explains Limits On Lobbyists 31/01/2018 Catherine Saez The engagement of actors such as industry, civil society, philanthropy and academia with the World Health Organization has been a subject of controversy, with some of those actors being potentially able to influence the work of the organisation. A framework for engagement with those stakeholders was agreed two years ago. At last week's Executive Board meeting, the new WHO director general explained that engagement with those actors, and notably industry, is worth the risk, which he said can be managed. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Antimicrobial Resistance The “Scariest” Public Health Issue, Needs Financial R&D Incentives, Industry Says 19/01/2018 Catherine Saez On the eve of the annual January World Health Organization Executive Board meeting, an alliance of pharmaceutical industries launched its first report on efforts made to curb antimicrobial resistance. The alliance also organised a conference on the report and on challenges of antimicrobial resistance, in particular the need for research and development incentives so that the industry can continue its efforts sustainably. Some light was also shed on the need to support access to diagnostics, and lower their prices. Continue reading -> New Local Pharmaceutical Plant Expected To Enhance Access To Drugs In Kenya 12/01/2018 Justus Wanzala Kenya’s pharmaceutical products manufacturing sector is hopeful it will experience significant growth after the Square Pharmaceuticals ltd (SPL) of Bangladesh commissioned a US$ 75 million plant in the East African nation this week. [A reminder: this story, like all of our stories, is completely free for almost every developing country in the world. Just sign up for a free password here!] Continue reading -> WHO: New Directors In Leadership Team Selected On Merit First 09/01/2018 William New The new World Health Organization director general last month announced a range of officials to serve as programme directors, touting the unusual achievement of naming almost all women to add to an overall women's majority in the senior leadership of the organisation - a first for the UN. Now after some questions arose over the choice of a Russian official to head up efforts against tuberculosis, the WHO defended its choices as fully merit-based, including in an email to Intellectual Property Watch and its sister publication Global Health Policy News. Continue reading -> Medicines Patent Pool Launches Search For Next Director 08/01/2018 William New A negotiator and fundraiser with extensive experience with the pharmaceutical industry. Those are some of the qualities the next Medicines Patent Pool executive director might have, according to a just-posted job announcement. Continue reading -> Greg Perry Resigns As Director Of Medicines Patent Pool 14/12/2017 William New After nearly five years as the executive director of the Medicines Patent Pool, Greg Perry has stepped down with little notice. [Update: the next day, it was announced that he has joined the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in Geneva.] Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
“We Must Engage With Industry” – WHO Director Explains Limits On Lobbyists 31/01/2018 Catherine Saez The engagement of actors such as industry, civil society, philanthropy and academia with the World Health Organization has been a subject of controversy, with some of those actors being potentially able to influence the work of the organisation. A framework for engagement with those stakeholders was agreed two years ago. At last week's Executive Board meeting, the new WHO director general explained that engagement with those actors, and notably industry, is worth the risk, which he said can be managed. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Antimicrobial Resistance The “Scariest” Public Health Issue, Needs Financial R&D Incentives, Industry Says 19/01/2018 Catherine Saez On the eve of the annual January World Health Organization Executive Board meeting, an alliance of pharmaceutical industries launched its first report on efforts made to curb antimicrobial resistance. The alliance also organised a conference on the report and on challenges of antimicrobial resistance, in particular the need for research and development incentives so that the industry can continue its efforts sustainably. Some light was also shed on the need to support access to diagnostics, and lower their prices. Continue reading -> New Local Pharmaceutical Plant Expected To Enhance Access To Drugs In Kenya 12/01/2018 Justus Wanzala Kenya’s pharmaceutical products manufacturing sector is hopeful it will experience significant growth after the Square Pharmaceuticals ltd (SPL) of Bangladesh commissioned a US$ 75 million plant in the East African nation this week. [A reminder: this story, like all of our stories, is completely free for almost every developing country in the world. Just sign up for a free password here!] Continue reading -> WHO: New Directors In Leadership Team Selected On Merit First 09/01/2018 William New The new World Health Organization director general last month announced a range of officials to serve as programme directors, touting the unusual achievement of naming almost all women to add to an overall women's majority in the senior leadership of the organisation - a first for the UN. Now after some questions arose over the choice of a Russian official to head up efforts against tuberculosis, the WHO defended its choices as fully merit-based, including in an email to Intellectual Property Watch and its sister publication Global Health Policy News. Continue reading -> Medicines Patent Pool Launches Search For Next Director 08/01/2018 William New A negotiator and fundraiser with extensive experience with the pharmaceutical industry. Those are some of the qualities the next Medicines Patent Pool executive director might have, according to a just-posted job announcement. Continue reading -> Greg Perry Resigns As Director Of Medicines Patent Pool 14/12/2017 William New After nearly five years as the executive director of the Medicines Patent Pool, Greg Perry has stepped down with little notice. [Update: the next day, it was announced that he has joined the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in Geneva.] Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Antimicrobial Resistance The “Scariest” Public Health Issue, Needs Financial R&D Incentives, Industry Says 19/01/2018 Catherine Saez On the eve of the annual January World Health Organization Executive Board meeting, an alliance of pharmaceutical industries launched its first report on efforts made to curb antimicrobial resistance. The alliance also organised a conference on the report and on challenges of antimicrobial resistance, in particular the need for research and development incentives so that the industry can continue its efforts sustainably. Some light was also shed on the need to support access to diagnostics, and lower their prices. Continue reading -> New Local Pharmaceutical Plant Expected To Enhance Access To Drugs In Kenya 12/01/2018 Justus Wanzala Kenya’s pharmaceutical products manufacturing sector is hopeful it will experience significant growth after the Square Pharmaceuticals ltd (SPL) of Bangladesh commissioned a US$ 75 million plant in the East African nation this week. [A reminder: this story, like all of our stories, is completely free for almost every developing country in the world. Just sign up for a free password here!] Continue reading -> WHO: New Directors In Leadership Team Selected On Merit First 09/01/2018 William New The new World Health Organization director general last month announced a range of officials to serve as programme directors, touting the unusual achievement of naming almost all women to add to an overall women's majority in the senior leadership of the organisation - a first for the UN. Now after some questions arose over the choice of a Russian official to head up efforts against tuberculosis, the WHO defended its choices as fully merit-based, including in an email to Intellectual Property Watch and its sister publication Global Health Policy News. Continue reading -> Medicines Patent Pool Launches Search For Next Director 08/01/2018 William New A negotiator and fundraiser with extensive experience with the pharmaceutical industry. Those are some of the qualities the next Medicines Patent Pool executive director might have, according to a just-posted job announcement. Continue reading -> Greg Perry Resigns As Director Of Medicines Patent Pool 14/12/2017 William New After nearly five years as the executive director of the Medicines Patent Pool, Greg Perry has stepped down with little notice. [Update: the next day, it was announced that he has joined the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in Geneva.] Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Antimicrobial Resistance The “Scariest” Public Health Issue, Needs Financial R&D Incentives, Industry Says 19/01/2018 Catherine Saez On the eve of the annual January World Health Organization Executive Board meeting, an alliance of pharmaceutical industries launched its first report on efforts made to curb antimicrobial resistance. The alliance also organised a conference on the report and on challenges of antimicrobial resistance, in particular the need for research and development incentives so that the industry can continue its efforts sustainably. Some light was also shed on the need to support access to diagnostics, and lower their prices. Continue reading -> New Local Pharmaceutical Plant Expected To Enhance Access To Drugs In Kenya 12/01/2018 Justus Wanzala Kenya’s pharmaceutical products manufacturing sector is hopeful it will experience significant growth after the Square Pharmaceuticals ltd (SPL) of Bangladesh commissioned a US$ 75 million plant in the East African nation this week. [A reminder: this story, like all of our stories, is completely free for almost every developing country in the world. Just sign up for a free password here!] Continue reading -> WHO: New Directors In Leadership Team Selected On Merit First 09/01/2018 William New The new World Health Organization director general last month announced a range of officials to serve as programme directors, touting the unusual achievement of naming almost all women to add to an overall women's majority in the senior leadership of the organisation - a first for the UN. Now after some questions arose over the choice of a Russian official to head up efforts against tuberculosis, the WHO defended its choices as fully merit-based, including in an email to Intellectual Property Watch and its sister publication Global Health Policy News. Continue reading -> Medicines Patent Pool Launches Search For Next Director 08/01/2018 William New A negotiator and fundraiser with extensive experience with the pharmaceutical industry. Those are some of the qualities the next Medicines Patent Pool executive director might have, according to a just-posted job announcement. Continue reading -> Greg Perry Resigns As Director Of Medicines Patent Pool 14/12/2017 William New After nearly five years as the executive director of the Medicines Patent Pool, Greg Perry has stepped down with little notice. [Update: the next day, it was announced that he has joined the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in Geneva.] Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New Local Pharmaceutical Plant Expected To Enhance Access To Drugs In Kenya 12/01/2018 Justus Wanzala Kenya’s pharmaceutical products manufacturing sector is hopeful it will experience significant growth after the Square Pharmaceuticals ltd (SPL) of Bangladesh commissioned a US$ 75 million plant in the East African nation this week. [A reminder: this story, like all of our stories, is completely free for almost every developing country in the world. Just sign up for a free password here!] Continue reading -> WHO: New Directors In Leadership Team Selected On Merit First 09/01/2018 William New The new World Health Organization director general last month announced a range of officials to serve as programme directors, touting the unusual achievement of naming almost all women to add to an overall women's majority in the senior leadership of the organisation - a first for the UN. Now after some questions arose over the choice of a Russian official to head up efforts against tuberculosis, the WHO defended its choices as fully merit-based, including in an email to Intellectual Property Watch and its sister publication Global Health Policy News. Continue reading -> Medicines Patent Pool Launches Search For Next Director 08/01/2018 William New A negotiator and fundraiser with extensive experience with the pharmaceutical industry. Those are some of the qualities the next Medicines Patent Pool executive director might have, according to a just-posted job announcement. Continue reading -> Greg Perry Resigns As Director Of Medicines Patent Pool 14/12/2017 William New After nearly five years as the executive director of the Medicines Patent Pool, Greg Perry has stepped down with little notice. [Update: the next day, it was announced that he has joined the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in Geneva.] Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO: New Directors In Leadership Team Selected On Merit First 09/01/2018 William New The new World Health Organization director general last month announced a range of officials to serve as programme directors, touting the unusual achievement of naming almost all women to add to an overall women's majority in the senior leadership of the organisation - a first for the UN. Now after some questions arose over the choice of a Russian official to head up efforts against tuberculosis, the WHO defended its choices as fully merit-based, including in an email to Intellectual Property Watch and its sister publication Global Health Policy News. Continue reading -> Medicines Patent Pool Launches Search For Next Director 08/01/2018 William New A negotiator and fundraiser with extensive experience with the pharmaceutical industry. Those are some of the qualities the next Medicines Patent Pool executive director might have, according to a just-posted job announcement. Continue reading -> Greg Perry Resigns As Director Of Medicines Patent Pool 14/12/2017 William New After nearly five years as the executive director of the Medicines Patent Pool, Greg Perry has stepped down with little notice. [Update: the next day, it was announced that he has joined the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in Geneva.] Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Medicines Patent Pool Launches Search For Next Director 08/01/2018 William New A negotiator and fundraiser with extensive experience with the pharmaceutical industry. Those are some of the qualities the next Medicines Patent Pool executive director might have, according to a just-posted job announcement. Continue reading -> Greg Perry Resigns As Director Of Medicines Patent Pool 14/12/2017 William New After nearly five years as the executive director of the Medicines Patent Pool, Greg Perry has stepped down with little notice. [Update: the next day, it was announced that he has joined the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in Geneva.] Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Greg Perry Resigns As Director Of Medicines Patent Pool 14/12/2017 William New After nearly five years as the executive director of the Medicines Patent Pool, Greg Perry has stepped down with little notice. [Update: the next day, it was announced that he has joined the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in Geneva.] Continue reading -> G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
G-Finder Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On US Funding Dangerous 13/12/2017 Catherine Saez A report released today on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is "unparalleled," and leads to a heavy concentration of global funding on HIV/AIDS, malaria and tuberculosis. This overreliance could also lead to change in total global funding, the report found. Continue reading -> Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Medicines Patent Pool Expands Its Patent Database To Cancer Treatments 12/12/2017 Catherine Saez The Medicines Patent Pool (MPP) announced today that MedsPaL, its database of information on the patent and licensing status of selected HIV, hepatitis C, and tuberculosis medicines, now extends to patented treatments on the World Health Organization Model List of Essential Medicines. New patents data include medicines for leukaemia, breast cancer and other cancer indications. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy